Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR407899A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo |
| Cohort 2 | EXPERIMENTAL | Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo |
| Name | Type | Description |
|---|---|---|
| SAR407899A | DRUG | Pharmaceutical form:capsule Route of administration: oral |
Inclusion criteria: * Male and female patients aged between 18 and 79 * Patients with chronic kidney disease (CKD-3) * Patients should be on stable ACE-I treatment (same type and regimen) for at least 2 months prior to screening * Body weight between 50.0 kg and 115.0 kg inclusive if male, between ...
Top 20 of 25 competitors
SAR407899A is an investigational small molecule being developed by Sanofi for the treatment of Chronic Kidney Disease. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under study to assess its safety and tolerability in patients.
SAR407899A is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is in Phase 1 clinical development for Chronic Kidney Disease, with a completed clinical trial evaluating its safety and tolerability.
SAR407899A is in Phase 1 clinical development. It is an investigational drug for Chronic Kidney Disease and has not yet received regulatory approval. A Phase 1 clinical trial has been completed to assess the safety and tolerability of repeated dosing in patients with stage 3 chronic kidney disease.
SAR407899A has one completed clinical trial registered under NCT01485900. This Phase 1 study evaluated repeated dosing to assess safety and tolerability in patients with Chronic Kidney Disease stage 3 who were on stable ACE inhibitor treatment. The trial enrolled 20 participants in Moldova and Romania.
SAR407899A is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Chronic Kidney Disease. The drug has completed a Phase 1 trial, but it remains under study and has not been authorized for commercial use by regulatory agencies.
SAR407899A is a small molecule being studied for Chronic Kidney Disease. Its specific molecular target has not been disclosed in available clinical trial information. The drug is in Phase 1 development, with a completed study focused on safety and tolerability in patients with chronic kidney disease.